A Novel Delivery Platform Based on Bacteriophage MS2 Virus-like Particles

Overview

Journal Virus Res

Specialty Microbiology

Date 2015 Sep 30

PMID 26415756

Citations 31

Authors

Yu Fu

Jinming Li

Affiliations

Soon will be listed here.

Abstract

Our objective here is to review the novel delivery platform based on Bacteriophage MS2 virus-like particles (VLPs), including introduction to their structure, their potential as a delivery platform, and their expected use in medicine and other fields. Bacteriophage MS2 VLPs are nanoparticles devoid of viral genetic material and can self-assemble from the coat protein into an icosahedral capsid. As a novel delivery platform, they possess numerous features that make them suitable and attractive for targeted delivery of RNAs or DNAs, epitope peptides, and drugs within the protein capsid. In short, as a novel delivery platform, MS2 VLPs are suitable for delivery of targeted agents and hold promise for use in diagnostics, vaccines, and therapeutic modalities.

Citing Articles

The RNA Landscape of In Vivo-Assembled MS2 Virus-Like Particles as mRNA Carriers Reveals RNA Contamination from Host Viruses.

Ma C, Yang M, Zhou W, Guo S, Zhang H, Gong J Nano Lett. 2025; 25(8):3038-3044.

PMID: 39932477 PMC: 11869999. DOI: 10.1021/acs.nanolett.4c04541.

Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.

Singh D, Haque S, Kim Y, Han I, Yadav D Front Immunol. 2024; 15:1455211.

PMID: 39720730 PMC: 11666570. DOI: 10.3389/fimmu.2024.1455211.

Significance of VLPs in Vlp-circRNA vaccines: a vaccine candidate or delivery vehicle?.

Gupta R, Arora K, Mehrotra Arora N, Kundu P RNA Biol. 2024; 21(1):17-28.

PMID: 39240021 PMC: 11382717. DOI: 10.1080/15476286.2024.2399307.

Tailored Viral-like Particles as Drivers of Medical Breakthroughs.

Travassos R, Martins S, Fernandes A, Correia J, Melo R Int J Mol Sci. 2024; 25(12).

PMID: 38928403 PMC: 11204272. DOI: 10.3390/ijms25126699.

Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.

Wang H, Yang Y, Xu Y, Chen Y, Zhang W, Liu T J Nanobiotechnology. 2024; 22(1):365.

PMID: 38918839 PMC: 11197292. DOI: 10.1186/s12951-024-02576-4.

References

Tumban E, Peabody J, Tyler M, Peabody D, Chackerian B . VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One. 2012; 7(11):e49751. PMC: 3501453. DOI: 10.1371/journal.pone.0049751. View

Johnson L, Frye T, Arnot A, Marquette C, Couture L, Gendron-Fitzpatrick A . Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine. 2005; 24(3):293-303. DOI: 10.1016/j.vaccine.2005.07.074. View

Sun S, Li W, Sun Y, Pan Y, Li J . A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2011; 407(1):124-8. DOI: 10.1016/j.bbrc.2011.02.122. View

Zhang L, Sun Y, Chang L, Jia T, Wang G, Zhang R . A novel method to produce armored double-stranded DNA by encapsulation of MS2 viral capsids. Appl Microbiol Biotechnol. 2015; 99(17):7047-57. PMC: 7079959. DOI: 10.1007/s00253-015-6664-4. View

Cadena-Nava R, Hu Y, Garmann R, Ng B, Zelikin A, Knobler C . Exploiting fluorescent polymers to probe the self-assembly of virus-like particles. J Phys Chem B. 2011; 115(10):2386-91. DOI: 10.1021/jp1094118. View

Zhan S, Li J, Xu R, Wang L, Zhang K, Zhang R . Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1. J Clin Microbiol. 2009; 47(8):2571-6. PMC: 2725685. DOI: 10.1128/JCM.00232-09. View

Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L . Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 2012; 279(7):1198-208. DOI: 10.1111/j.1742-4658.2012.08512.x. View

Borodavka A, Tuma R, Stockley P . Evidence that viral RNAs have evolved for efficient, two-stage packaging. Proc Natl Acad Sci U S A. 2012; 109(39):15769-74. PMC: 3465389. DOI: 10.1073/pnas.1204357109. View

Valegard K, Liljas L, Fridborg K, Unge T . Structure determination of the bacteriophage MS2. Acta Crystallogr B. 1991; 47 ( Pt 6):949-60. DOI: 10.1107/s0108768191006821. View

10.

Pan Y, Jia T, Zhang Y, Zhang K, Zhang R, Li J . MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice. Int J Nanomedicine. 2012; 7:5957-67. PMC: 3518289. DOI: 10.2147/IJN.S37990. View

11.

Mastico R, Talbot S, Stockley P . Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J Gen Virol. 1993; 74 ( Pt 4):541-8. DOI: 10.1099/0022-1317-74-4-541. View

12.

Lago H, Parrott A, Moss T, Stonehouse N, Stockley P . Probing the kinetics of formation of the bacteriophage MS2 translational operator complex: identification of a protein conformer unable to bind RNA. J Mol Biol. 2001; 305(5):1131-44. DOI: 10.1006/jmbi.2000.4355. View

13.

Hu Y, Zandi R, Anavitarte A, Knobler C, Gelbart W . Packaging of a polymer by a viral capsid: the interplay between polymer length and capsid size. Biophys J. 2007; 94(4):1428-36. PMC: 2212672. DOI: 10.1529/biophysj.107.117473. View

14.

Drosten C, Seifried E, Roth W . TaqMan 5'-nuclease human immunodeficiency virus type 1 PCR assay with phage-packaged competitive internal control for high-throughput blood donor screening. J Clin Microbiol. 2001; 39(12):4302-8. PMC: 88540. DOI: 10.1128/JCM.39.12.4302-4308.2001. View

15.

Peabody D, Lim F . Complementation of RNA binding site mutations in MS2 coat protein heterodimers. Nucleic Acids Res. 1996; 24(12):2352-9. PMC: 145953. DOI: 10.1093/nar/24.12.2352. View

16.

Gardner T, Elzey B, Hahn N . Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer. Hum Vaccin Immunother. 2012; 8(4):534-9. DOI: 10.4161/hv.19795. View

17.

Wu M, Sherwin T, Brown W, Stockley P . Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine. 2007; 1(1):67-76. DOI: 10.1016/j.nano.2004.11.011. View

18.

Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y . MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009; 60(4):1065-75. DOI: 10.1002/art.24436. View

19.

Kreiter S, Selmi A, Diken M, Koslowski M, Britten C, Huber C . Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010; 70(22):9031-40. DOI: 10.1158/0008-5472.CAN-10-0699. View

20.

Qiu P, Ziegelhoffer P, Sun J, Yang N . Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 1996; 3(3):262-8. View